Gensaic Files IPO Prospectus Following Landmark $354M-per-Target Deal with Novo Nordisk

On March 3, Novo Nordisk and Gensaic, an AI pharmaceutical company, reached a licensing and discovery collaboration. This collaboration combines Novo Nordisk's deep therapeutic knowledge and drug development experience with Gensaic's novel protein design technology to discoverTissue-targeting ligands, and develop new therapeutic candidates to treat metabolic cardiovascular diseases through undisclosed targets.

According to the agreement,Gensaic Is Eligible for Each TargetTargetHighest$354 million in upfront payments, development and commercial milestones, and tiered royalties. Novo Nordisk will also reimburse R&D costs and participate.ToFuture Round of FinancingIn China.A senior executive of Novo Nordisk will join as a non-voting observer member.The Board of Directors of Gensaic, Inc.

With the development of weight-loss drugsAs the competition heats up, innovative therapies, next-generation compounds, and precise delivery will become the key areas where MNCs place their bets to capture the next "critical battleground" – the metabolic disease market.

Tissue targeting of delivered ligands can deliver drugs to specific sites or cell populations in the body, serving as the foundation for unlocking the next generation of precision medicines. However, the liver(such as siRNA)Targeting tissues beyond remains a challenge, requiring the discovery of new biological mechanisms to deliver drugs to selected organs or cell types.It is not difficult to see that the main purpose of Novo Nordisk's exploratory cooperation is to find and open up new paths for the treatment of metabolism-related diseases.

Gensaic was initially spun off from MIT., headquartered in Cambridge, Massachusetts, the team is jointly composed of award-winning doctors, bioengineers, and machine learning scientists, aiming to advance a key goal: finding payloads that can be selectively delivered to any tissue. Their initial focus is on gene-encoded nanoparticles (GeNPs) and small interfering RNA (siRNA) payloads.

Currently, Gensaic combines AI-driven protein design with biological insights,Launch a unique proprietary technology platform Functional Optimization by Recursive Genetic Evolution (FORGE™), combiningWet Lab Protein Evolution, DiscoveryBrand NewLigand.This platform combines unbiased protein evolution with machine-guided design to map and harness complex protein interaction networks, seeking new mechanisms of action for tissue-selective intracellular delivery.

“Tissue targeting has such great potential——Not only in the available pathways, but also in the treatable diseases, Head of Novo Nordisk Bioinnovation CenterUli StilzMentioned in an interview with the media, "Gensaic Technology Brings a Whole NewMethod, capable of screening targeting tissue ligands in an unbiased manner. By"By combining Gensaic's technology with our team's deep understanding of diseases and drug development, we have the potential to reach challenging targets while enhancing efficacy and reducing potential side effects."

"The currently known targeted delivery mechanisms are very limited, and we need to continuously explore new targets and delivery pathways," said Lavi Erisson, CEO of Gensaic.GensaicTechnologyCan design something superior to what is found in nature.BenefitProtein usedStructure，To help usFindChinaNew Mechanism of Action,IncludingNew Receptor SurfaceComponent orCan mediate more effectivelyDeliveredEpitope.

Interestingly, the collaboration between Novo Nordisk and Gensaic dates back to 2022 — reflecting Novo Nordisk's ongoing strategy to focus on innovative early-stage Biotech.

Uli Stilz, head of Novo Nordisk's Bio Innovation Hub, said that the Bio Innovation Hub is responsible for seeking, funding, and supporting promising early-stage research, and every year it reviews 5~10 very young Biotech companiesDiscussion before cooperation. In 2022, although Gensaic's R&D focus at that time did not align with Novo Nordisk's development priorities, Novo Nordisk still provided them with laboratories, guidance support, and related investments.

He mentioned that under this risk-taking model, not all products can establish partnerships, let alone commercially successful ones. However, when encountering an excellent team and a cutting-edge idea, even if there is no specific collaboration in place, Novo Nordisk has enough confidence to participate in high-risk "bets."

The long-term strategic approach has also been carried over into Novo Nordisk's formal collaboration. Taking this partnership as an example, it will still take a considerable amount of time to derive clinical leads from the Gensaic platform. However, Novo Nordisk is prepared for long-term involvement: in addition to committing to substantial milestone payments and tiered royalties for each target, Novo Nordisk will also reimburse R&D costs and participate in future financing rounds of Gensaic.A senior executive will join Gensaic's board of directors as a non-voting observer member.

Betting on frontier hotspots, focusing on key areas, building a Biotech innovation ecosystem, and laying out the next-generation therapies may be the ultimate goal of its innovation strategy.

One category focuses on cutting-edge technology trends and products, such as the AI-driven protein pharmaceuticals field represented by Gensaic.By the end of 2022, Novo Nordisk entered into a global exclusive licensing agreement with Ventus Therapeutics, which also applies AI proteomics in drug development, to obtain the development and commercialization rights for a peripheral inhibitor targeting NOD-like receptor thermal protein domain-associated protein 3 (NLRP3). Novo Nordisk made an upfront payment of $70 million and provided research funding, with potential additional milestone payments totaling $633 million in the future.

One category focuses on key areas, building a product matrix to form synergistic benefits with related products. In the field of metabolic cardiovascular diseases highlighted this time, Novo Nordisk has been continuously investing for many years.

In September 2023, Novo Nordisk collaborated with German company Evotec to launch the accelerator platform LAB eN², targeting the cardiometabolic disease field. The platform has signed agreements with four academic institutions: Harvard University, Massachusetts General Hospital, Yale University, and Beth Israel Deaconess Medical Center. LAB eN² will provide funding, disease expertise, and technology, along with Evotec's drug discovery and development resources, and Novo Nordisk’s clinical, regulatory, and commercialization guidance. Additionally, Novo Nordisk will have the option to invest in and further develop certain products.

In the same month, Novo Nordisk collaborated with AI drug development company Valo Health, utilizing its Opal platform and real-world patient datasets to discover and develop novel cardiometabolic programs.IntroducedThree Preclinical Programs for Cardiometabolic Diseases, $60 Million Upfront Payment, Potential DealTotal amount up to$2.7 billion.

In addition, Novo Nordisk collaborates with the Broad Institute, utilizing large-scale cell screening.Committed to DiscoveryNew Targets for Type 2 Diabetes and Cardiometabolic Diseases.Within the next three years, advance at leastThree projects, two of which aim to identify drug targets for clinically important subtypes of type 2 diabetes; one project aims to unravel the genetic causes of cardiac fibrosis or cardiac scarring.

In October, Novo Nordisk acquired KBP Biosciences, a Singapore-based company in Phase 3 clinical trials.Antihypertensive DrugsOcedurenone, with a transaction amount of up to 1.3 billion US dollars.

Overall, Novo Nordisk's collaboration partners are very diverse, including accelerator platforms focused on early scientific research exploration and achievement transformation, BroadThere are also AI pharmaceutical companies that focus on platform-based technologies, such as Gensaic and Valo Health, as well as clinical-stage biotech companies that have directly achieved pipeline acquisitions.

In essence, Novo Nordisk aims to establish a third pillar—enhancing innovation capabilities and seeking a long-term, sustainable development path for multinational corporations (MNCs)—through investments, mergers and acquisitions, and collaborations, beyond the two major barriers of pipeline assets and technology platforms.